CRBP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CRBP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Corbus Pharmaceuticals Holdings's share price for the quarter that ended in Dec. 2024 was $11.8. Corbus Pharmaceuticals Holdings's Shares Outstanding (EOP) for the quarter that ended in Dec. 2024 was 12.18 Mil. Therefore, Corbus Pharmaceuticals Holdings's market cap for the quarter that ended in Dec. 2024 was $143.71 Mil.
Corbus Pharmaceuticals Holdings's quarterly market cap declined from Jun. 2024 ($520.33 Mil) to Sep. 2024 ($251.25 Mil) and declined from Sep. 2024 ($251.25 Mil) to Dec. 2024 ($143.71 Mil).
Corbus Pharmaceuticals Holdings's annual market cap increased from Dec. 2022 ($13.83 Mil) to Dec. 2023 ($26.72 Mil) and increased from Dec. 2023 ($26.72 Mil) to Dec. 2024 ($143.71 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Corbus Pharmaceuticals Holdings's Enterprise Value for Today is $-62.52 Mil.
The historical data trend for Corbus Pharmaceuticals Holdings's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corbus Pharmaceuticals Holdings Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Market Cap | Get a 7-Day Free Trial |
![]() |
![]() |
123.56 | 77.10 | 13.83 | 26.72 | 143.71 |
Corbus Pharmaceuticals Holdings Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Market Cap | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
26.72 | 412.29 | 520.33 | 251.25 | 143.71 |
For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where Corbus Pharmaceuticals Holdings's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Corbus Pharmaceuticals Holdings's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as
Market Cap (A: Dec. 2024 ) | = | Share Price (A: Dec. 2024 ) | * | Shares Outstanding (EOP) (A: Dec. 2024 ) |
= | $11.8 | * | 12.179 | |
= | $143.71 |
Corbus Pharmaceuticals Holdings's Market Cap for the quarter that ended in Dec. 2024 is calculated as
Market Cap (Q: Dec. 2024 ) | = | Share Price (Q: Dec. 2024 ) | * | Shares Outstanding (EOP) (Q: Dec. 2024 ) |
= | $11.8 | * | 12.179 | |
= | $143.71 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corbus Pharmaceuticals Holdings (NAS:CRBP) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Yuval Cohen | director, officer: Chief Executive Officer | C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
Sean F. Moran | officer: Chief Financial Officer | 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046 |
Yong Ben | director | 500 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
Anne Altmeyer | director | 500 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
Craig Stuart Millian | officer: Chief Commercial Officer | C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
Rachael Louise Brake | officer: Chief Scientific Officer | 21 MANCHESTER PLACE, NATICK MA 01760 |
George Golumbeski | director | C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Peter Salzmann | director | 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016 |
Barbara White | officer: Chief Medical Officer | C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
Robert Paul Discordia | officer: Chief Operating Officer | C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
Rachelle Suzanne Jacques | director | C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
David P Hochman | director | 15 WESTON HILL RD., RIVERSIDE CT 06878 |
John Kenneth Jenkins | director | C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
Paris Panayiotopoulos | director | ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Avery W Catlin | director | 241 CENTRAL STREET, HINGHAM MA 02043 |
From GuruFocus
By Marketwired • 05-09-2024
By Marketwired • 05-23-2024
By GuruFocus Research • 09-25-2024
By Marketwired • 09-05-2024
By GuruFocus News • 10-11-2024
By Marketwired • 08-20-2024
By Marketwired • 07-30-2024
By Marketwired • 01-06-2025
By Marketwired • 11-07-2024
By Marketwired • 05-01-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.